1 / 18

Presented By Mario Sznol at 2014 ASCO Annual Meeting

Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in<br /> advanced melanoma (MEL) . Presented By Mario Sznol at 2014 ASCO Annual Meeting. Disclosures.

roy
Télécharger la présentation

Presented By Mario Sznol at 2014 ASCO Annual Meeting

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in<br /> advanced melanoma (MEL) Presented By Mario Sznol at 2014 ASCO Annual Meeting

  2. Disclosures Presented By Mario Sznol at 2014 ASCO Annual Meeting

  3. Ipilimumab and Nivolumab Clinical Experience in Patients with Advanced Melanoma Presented By Mario Sznol at 2014 ASCO Annual Meeting

  4. Objectives Presented By Mario Sznol at 2014 ASCO Annual Meeting

  5. CA209-004 Phase I Study: Dose Cohorts Presented By Mario Sznol at 2014 ASCO Annual Meeting

  6. Patient Demographics Presented By Mario Sznol at 2014 ASCO Annual Meeting

  7. Activity Summary: Concurrent and Sequenced Cohorts from 004 Presented By Mario Sznol at 2014 ASCO Annual Meeting

  8. Response in Target Lesions Presented By Mario Sznol at 2014 ASCO Annual Meeting

  9. Slide 9 Presented By Mario Sznol at 2014 ASCO Annual Meeting

  10. Characteristics of Response Presented By Mario Sznol at 2014 ASCO Annual Meeting

  11. Safety Overview Presented By Mario Sznol at 2014 ASCO Annual Meeting

  12. ORR by BRAF Status for Concurrent Cohorts Presented By Mario Sznol at 2014 ASCO Annual Meeting

  13. ORR by PD-L1 Status (5% cutoff) Presented By Mario Sznol at 2014 ASCO Annual Meeting

  14. ORR by Ipilimumab Exposure at Time <br />of Nivolumab Treatment Presented By Mario Sznol at 2014 ASCO Annual Meeting

  15. Overall Survival for Concurrent <br />Therapy by Dose Cohort Presented By Mario Sznol at 2014 ASCO Annual Meeting

  16. Survival Endpoints for Concurrent and Sequential Therapy by Dose Cohort Presented By Mario Sznol at 2014 ASCO Annual Meeting

  17. Conclusions Presented By Mario Sznol at 2014 ASCO Annual Meeting

  18. Acknowledgments Presented By Mario Sznol at 2014 ASCO Annual Meeting

More Related